journal article·2021-12-08

Dual-Targeted Nanoplatform Regulating the Bone Immune Microenvironment Enhances Fracture Healing

Wu Zhou, Ze Lin, Yuan Xiong, Hang Xue, Wen Song, Tao Yu, Lang Chen, Yiqiang Hu, Adriana C. Panayi, Yun Sun, Faqi Cao, Guodong Liu, Liangcong Hu, Chenchen Yan, Xudong Xie, Wenxiu Qiu, Bobin Mi, Guohui Liu

ACS Applied Materials & Interfaces· Volume 13· Issue 48
Publisher page

Abstract

The immune system and skeletal system are closely linked. Macrophages are one of the most important immune cells for bone remodeling, playing a prohealing role mainly through M2 phenotype polarization. Baicalein (5,6,7-trihydroxyflavone, BCL) has been well documented to have a noticeable promotion effect on M2 macrophage polarization. However, due to the limitations in targeted delivery to macrophages and the toxic effect on other organs, BCL has rarely been used in the treatment of bone fractures. In this study, we developed mesoporous silica and Fe3O4 composite-targeted nanoparticles loaded with BCL (BCL@MMSNPs-SS-CD-NW), which could be magnetically delivered to the fracture site. This induced macrophage recruitment in a targeted manner, polarizing them toward the M2 phenotype, which was demonstrated to induce mesenchymal stem cells (MSCs) toward osteoblastic differentiation. The mesoporous silicon nanoparticles (MSNs) were prepared with surface sulfhydrylation and amination modification, and the mesoporous channels were blocked with β-cyclodextrin. The outer layer of the mesoporous silicon was added with an amantane-modified NW-targeting peptide to obtain the targeted nanosystem. After entering macrophages, BCL could be released from nanoparticles since the disulfide linker could be cleaved by intracellular glutathione (GSH), resulting in the removal of cyclodextrin (CD) gatekeeper, which is a key element in the pro-bone-remodeling functions such as anti-inflammation and induction of M2 macrophage polarization to facilitate osteogenic differentiation. This nanosystem passively accumulated in the fracture site, promoting osteogenic differentiation activities, highlighting a potent therapeutic benefit with high biosafety.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone Metabolism and Diseases · Immune cells in cancer · S100 Proteins and Annexins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan 430022, China

Institute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China

Department of Orthopedic Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China

Department of Plastic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02152, United States

Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Medical Center of Trauma and War Injuries, Daping Hospital, Army Medical University, Chongqing 400042, China

Funding

Ministry of Science and Technology of the People's Republic of China · Health Commission of Hubei Province · China Postdoctoral Science Foundation · Wuhan Union Hospital · National Natural Science Foundation of China · Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration

References (60)

Show source-provided references
1. 10.1001/jamasurg.2016.277510.1001/jamasurg.2016.2775 ↗
2. 10.1038/7944910.1038/79449 ↗
3. 10.2106/JBJS.20.0113910.2106/JBJS.20.01139 ↗
4. 10.1016/j.actbio.2021.04.01010.1016/j.actbio.2021.04.010 ↗
5. 10.1002/smll.20200699210.1002/smll.202006992 ↗
6. 10.7150/thno.3693010.7150/thno.36930 ↗
7. 10.1126/sciadv.150178010.1126/sciadv.1501780 ↗
8. 10.1002/hep.3007110.1002/hep.30071 ↗
9. 10.1038/cdd.2008.8510.1038/cdd.2008.85 ↗
10. 10.1186/s12986-018-0327-210.1186/s12986-018-0327-2 ↗
11. 10.1016/j.apsb.2020.06.00510.1016/j.apsb.2020.06.005 ↗
12. 10.1016/j.biopha.2019.10910210.1016/j.biopha.2019.109102 ↗
13. 10.1186/s12951-020-00622-510.1186/s12951-020-00622-5 ↗
14. 10.1186/s12951-020-00674-710.1186/s12951-020-00674-7 ↗
15. 10.1186/s12951-020-00663-w10.1186/s12951-020-00663-w ↗
16. 10.1002/smll.20200549910.1002/smll.202005499 ↗
17. 10.1002/smll.20200601210.1002/smll.202006012 ↗
18. 10.1002/smll.20200351710.1002/smll.202003517 ↗
19. 10.1016/j.cclet.2018.10.03810.1016/j.cclet.2018.10.038 ↗
20. 10.7150/thno.4041410.7150/thno.40414 ↗
21. 10.1016/j.cclet.2020.07.01010.1016/j.cclet.2020.07.010 ↗
22. 10.1166/jbn.2020.294610.1166/jbn.2020.2946 ↗
23. 10.1166/jbn.2020.291910.1166/jbn.2020.2919 ↗
24. 10.1016/j.addr.2021.03.01810.1016/j.addr.2021.03.018 ↗
25. 10.1002/advs.20200273810.1002/advs.202002738 ↗
26. 10.1016/j.biomaterials.2015.10.05310.1016/j.biomaterials.2015.10.053 ↗
27. 10.1021/acsnano.7b0911210.1021/acsnano.7b09112 ↗
28. 10.1155/2021/885176310.1155/2021/8851763 ↗
29. 10.1016/j.omtn.2020.08.01410.1016/j.omtn.2020.08.014 ↗
30. 10.1161/CIRCRESAHA.120.31880510.1161/CIRCRESAHA.120.318805 ↗
31. 10.1172/JCI13784510.1172/JCI137845 ↗
32. 10.1155/2021/667827610.1155/2021/6678276 ↗
33. 10.1016/j.redox.2020.10183410.1016/j.redox.2020.101834 ↗
34. 10.1016/j.ijbiomac.2021.04.02510.1016/j.ijbiomac.2021.04.025 ↗
35. 10.1016/j.bone.2021.11596910.1016/j.bone.2021.115969 ↗
36. 10.1016/j.biomaterials.2020.12046410.1016/j.biomaterials.2020.120464 ↗
37. 10.3390/nu1210299910.3390/nu12102999 ↗
38. 10.1016/j.bone.2020.11562710.1016/j.bone.2020.115627 ↗
39. 10.1002/advs.20200232810.1002/advs.202002328 ↗
40. 10.1039/d0tb00282h10.1039/d0tb00282h ↗
41. 10.1016/j.engreg.2020.12.00110.1016/j.engreg.2020.12.001 ↗
42. 10.1016/j.engreg.2021.09.00110.1016/j.engreg.2021.09.001 ↗
43. 10.34133/2020/490718510.34133/2020/4907185 ↗
44. 10.1155/2021/883515610.1155/2021/8835156 ↗
45. 10.1016/j.ijpharm.2021.12054610.1016/j.ijpharm.2021.120546 ↗
46. 10.1002/ctm2.15410.1002/ctm2.154 ↗
47. 10.1016/j.ijpharm.2020.11954610.1016/j.ijpharm.2020.119546 ↗
48. 10.1002/smll.20190404410.1002/smll.201904044 ↗
49. 10.1182/blood-2004-10-391510.1182/blood-2004-10-3915 ↗
50. 10.1002/jcp.2629310.1002/jcp.26293 ↗
51. 10.1007/s11064-017-2179-y10.1007/s11064-017-2179-y ↗
52. 10.2147/OTT.S25785210.2147/OTT.S257852 ↗
53. Zhao X. · Am. J. Cancer Res. · 2018 · 8 · 1528
54. 10.1007/s00011-013-0639-710.1007/s00011-013-0639-7 ↗
55. 10.1016/j.fct.2012.12.00610.1016/j.fct.2012.12.006 ↗
56. 10.3390/molecules2301022310.3390/molecules23010223 ↗
57. 10.1016/j.bone.2017.04.01110.1016/j.bone.2017.04.011 ↗
58. 10.1142/S0192415X1750032X10.1142/S0192415X1750032X ↗
59. 10.1111/jcmm.1483210.1111/jcmm.14832 ↗
60. 10.1016/j.fct.2008.08.01610.1016/j.fct.2008.08.016 ↗